M&A / Deals Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal Pharmaceutical Business ReviewThe proposed offer is set at SFr44.31 per share for 100% of PolyPeptide's fully diluted share capital, excluding treasury shares.Read full story pharminent July 20, 2026 (Last updated: July 23, 2026) Pharmaceutical Business Review The proposed offer is set at SFr44.31 per share for 100% of PolyPeptide’s fully diluted share capital, excluding treasury shares. Read full story Post navigation Previous: FDA Converts Novartis’ Fabhalta to Full Approval in IgA NephropathyNext: Lundbeck preps for key bexicaserin data around year-end Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
